Considering Needle Phobia among Adult Patients During Mass COVID-19 Vaccinations

Ashley S. Love1 and Robert J. Love2

Abstract
As mass vaccination is underway to combat the COVID-19 pandemic and achieve herd immunity, healthcare professionals need to recognize the fear and phobia of needles among their patients. Approximately 11.5 to 66 million U.S. adults may suffer from this condition. This population often avoids seeking medical care including vaccinations. The exact number of people suffering from this phobia is unknown, and the potential years of life lost in the American health care system cannot be estimated accurately. The resistance to vaccinations among this population may delay achieving herd immunity to end this current pandemic. An overview of needle phobia, vaccinations, and current treatments are explored. The use of telemedicine could prove critical for reaching this population as well as those who are hesitant about vaccinations. Providing education to healthcare providers to identify and manage these patients during the pandemic is necessary.

Keywords
COVID-19, pandemic, vaccinations, needle phobia, telemedicine, herd immunity, education, needle fear, blood-injection-injury

Introduction
A global public health emergency was officially declared on January 30, 2020 due to the novel coronavirus disease 2019 (COVID-19) outbreak,1 and the pandemic was confirmed on March 11, 2020.2 In the United States, over 29,052,862 cases were diagnosed, and 527,726 people have died as of March 11, 2021.3 Strict public health methods were applied to prevent the transmission of this novel virus. Passengers on cruise ships were quarantined on military bases in February, and the first community acquired COVID-19 was confirmed in California by the end of February.4,5 The Centers for Disease Control and Prevention recommended implementation of physical distancing, masks, and handwashing.6 School and business closings as well as any indoor activities involving large gatherings were restricted.8 California was the first state to declare “stay-at-home” orders on March 19, 2020,9 and many other states followed.8

Vaccinations
The rush to produce a viable vaccine to combat this virus proved successful. The U.S. Food and Drug Administration (FDA) approved the emergency use of 2 vaccines that were developed by Pfizer/BioNTech and Moderna in December 2020.9 As of March 11, 2021, 19.3% of the total population received at least one dose, and 10.2% have been fully vaccinated since December 14, 2020.10 The FDA also approved emergency use of Johnson and Johnson (Janssen COVID-19) vaccine on February 27, 2021.9

Since there is no cure for COVID-19, the optimal intervention strategy to mitigate disease propagation is proactive vaccination to develop herd immunity. The percentage of people who have been vaccinated or had COVID-19 at this time is uncertain.11 Approximately 24% of the United States population is under 19 years of age.12 To achieve herd immunity quickly, a maximum number of adults must be vaccinated since there are no approved COVID-19 vaccines for children available. Among the remaining 76% of the population, a segment will refuse to be vaccinated for different reasons. A portion of those individuals may have

1University of the Incarnate Word, San Antonio, TX, USA
2David Grant Medical Center, Travis AFB, CA, USA

Corresponding Author:
Ashley S. Love, University of the Incarnate Word, 4301 Broadway Street, CPO 293, San Antonio, TX 78209, USA.
Email: aslove@uiwtx.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
various ideological objections to the COVID-19 vaccines (or vaccines in general) or vaccine hesitant; they may or may not be overcome with appropriate education that focuses on the safety, mechanism of action, and the importance of compliance for the good of public safety as opposed to individual benefits. Another group of adults is expected to decline vaccination based on needle phobia. For example, McLenon and Rogers found 1 out of 6 adult patients did not receive influenza vaccinations due to needle phobia. This group may be challenging to recruit into compliance with education about the relative importance of vaccination and alternative approaches to mitigate their phobic avoidance of injections of any kind. Due to the mutations of the SARS-CoV-2 strain, a majority of the population will most likely need to receive an annual COVID-19 vaccination once the herd immunity is achieved. The subject of needle phobia needs to be considered as mass vaccinations programs are increasingly implemented to achieve and sustain herd immunity.

Prevalence of Needle Phobia and Definition

Reported prevalence rates of needle phobia widely diverge in the literature ranging from 3.5% to 20%. Two research studies have found about 3.5% to 4% of population have needle phobia. Hamilton found that 10% of the population suffered from needle phobia. Taddio et al and Target Harris International study showed over 20% of the population had a needle phobia. These estimates suggest that between 11.5 and 66 million people in the U.S. population suffer from needle phobia.

Definitions of needle fear and needle phobia are not separately defined in previous epidemiological studies. Also, a few epidemiological studies on needle phobia exist. Needle fear is an induced anxiety when needles or injections are used. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), groups needle phobia as part of specific phobias of blood-injection-injury type. Needle phobia is anxiety that is out of proportion to the threat in the environment and event. Estimating the number of patients who may avoid vaccination due to needle phobia is difficult because this group is known to avoid contact with the medical system.

Possible Causes of Needle Phobia

Needle phobia may be trigged due to our genetics, environment, and experiences. Needle objects for greater chance of survival. Four out of five adults with needle phobia stated they had a first-degree relative with this fear. Furthermore, patients with needle fear or phobia may experience vasovagal syncope when confronted with needles/needle injections. Syncope may be a defense mechanism to protect the heart and the brain with vasovagal reflex and bradycardia. Bucci et al observed that negative experiences with vaccination may lead to future vaccine refusals. Other studies showed pain and fear with prior immunization contributed to future noncompliance. A long-lasting negative childhood immunization experience among ages 4 to 6 years old may be associated with fear and noncompliance of vaccination throughout adulthood. As many as 2 out of 3 people are afraid of needles.

Current Treatment Options for Needle Phobia

Historically the treatment of blood injection-injury phobia has received a relatively low priority, since treatment for this phobia only raises serious concern in relatively rare cases where a patient’s phobic avoidance of necessary procedures (eg, surgery) and/or injectable/infusible treatments (eg, transfusion, intravenous antibiotics, insulin, etc.) becomes life-threatening. During the COVID-19 pandemic, identification and treatment of needle phobia are expected to be priorities when vaccine supplies become sufficient to inoculate every eligible person because many Americans will not agree to vaccination due to phobic avoidance. Vaccination refusal by phobic avoiders could place other individuals at unnecessary risk of infection (eg, children under 16) and endanger the general public by undermining herd immunity.

Unlike other anxiety disorders, no psychotropic interventions have proven to be reliably efficacious for the treatment of specific phobia. Administration of benzodiazepines was the most commonly used medication strategy, but it resulted in minimal benefit that was not sustained over time and worsened phobic patients’ symptoms over time. In contrast to medications, exposure-based therapies have repeatedly demonstrated sustained benefits with advantages over other therapeutic alternatives including medications, systematic desensitization (relaxation therapy), and no treatment.

Delivery of exposure therapy to patients to mitigate risk of phobic avoidance is likely a practical option, based on the relatively uncomplicated nature of the techniques involved and low cost. Exposure therapy is considered the mainstay of treatment for specific phobia with demonstrated response rates as high as 90%. Augmenting exposure therapy with the technique of applied tension has demonstrated superior efficacy to other treatments; applied tension is the practice of repeated contractions of large muscle groups to counteract the vasovagal response that often accompanies blood-injection-injury phobias while being exposed to phobia triggers. It is currently recommended as initial treatment. An additional practical benefit of exposure therapy in the setting of pandemic isolation, it should be possible to develop a vaccination targeted
interventions utilizing computer based training modules. Computer-led exposure versus face-to-face sessions with therapist-led exposure yielded similar results among anxiety patients. An additional area for future development would likely involve the use of virtual reality (VR) technologies. The potential advantages of VR observed in various studies are equivalent to or possibly even superior to the results of real-life exposure. VR exposure has also been associated with a lower refusal rate as compared to real-life exposure strategies.

Conclusion

Vaccinations are critical public health interventions to decrease mortality and morbidity among the population. There is an urgency to vaccinate everyone. Blood-injection-injury phobia, which includes needle phobia, can threaten life by causing avoidance of medical and surgical procedures including blood transfusions, dental procedures, insulin, and other injectable medication as well as refusal of vaccinations. Screening efforts can help reach underserved members of the community who are vaccine resistant. To identify these patients, administering online screening using DSM-5 “Cross Cutting Screener for Phobia” in primary care, community health clinics, university health clinics, and through insurance companies may help to identify those who do not show up for vaccinations.

Once these individuals are identified through screening, healthcare providers can provide pre-clinical support as well as support for similarly affected family members. Telemedicine would be a good alternative for patients who have needle phobia during this pandemic. As stated previously, augmented exposure therapy can be provided effectively via telemedicine with benefits to both the patient and the society.

A significant way to increase vaccine acceptance is compassionate acknowledgment of this fear and phobia among millions of the U.S. adults. McMurtry et al described that vaccination experiences for some people were not “just a poke.” Validating that phobic responses have been associated with evolutions and genetics may decrease patients’ resistance to treatment by mitigate patient embarrassment. Healthcare professionals can benefit from education focused on identifying and managing various manifestations of needle phobia among adults. Until alternative ways to vaccinate for COVID-19 are available (ie, nasal spray), this phobia should be taken into consideration as the COVID-19 vaccinations continue.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Ashley S. Love https://orcid.org/0000-0002-4024-796X

References

1. World Health Organization. WHO emergencies coronavirus emergency committee second meeting—30 January 2020. Accessed January 11, 2021. https://www.who.int/docs/default-source/coronaviruse/transcripts/who-emergencies-committee-for-pneumonia-due-to-the-novel-coronavirus-2019-ncov-press-briefing-transcript-30012020.pdf?sfvrsn=c9463ac1_2
2. World Health Organization. Virtual press conference on COVID-19—11 March 2020. Accessed January 20, 2021. https://www.who.int/digital-library/events/2020-full-and-final-11mar2020.pdf?sfvrsn=cb432bfb_2
3. Centers for Disease Control and Prevention. CDC COVID data tracker. Accessed March 11, 2021. https://covid.cdc.gov/covid-data-tracker/#casesper100klast7days
4. Centers for Disease Control and Prevention. CDC confirms possible instance of community spread of COVID-19 in U.S. Accessed January 20, 2021. https://www.cdc.gov/media/releases/2020/s0226-Covid-19-spread.html
5. Jorden MA, Rudman SL, Villarino E, et al. Evidence for limited early spread of COVID-19 within the United States, January–February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:690-694. doi:10.15585/mmwr.mm6922e1
6. Centers for Disease Control and Prevention. Preventing the spread of COVID-19 in a variety of settings throughout your community. Accessed January 11, 2021, https://www.cdc.gov/coronavirus/2019-ncov/php/open-america/infection-control.html
7. State of California. Executive order N-33-20. 2020. Accessed January 20, 2021. https://www.gov.ca.gov/wp-content/uploads/2020/03/3.19.20-attested EO-N-33-20-COVID-19-HEALTH-ORDER.pdf
8. Moreland A, Herlihy C, Tynan MA, et al. Timing of state and territorial COVID-19 stay-at-home orders and changes in population movement—United States, March 1–May 31, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1198-1203. doi:10.15585/mmwr.mm6935a2external
9. U.S Food and Drug Administration. Vaccines and related biological products advisory committee December 10, 2020, meeting announcement. Accessed February 28, 2021. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine
10. Centers for Disease Control and Prevention. CDC COVID data tracker: COVID-19 vaccinations in the United States. Accessed March 11, 2021. https://covid.cdc.gov/covid-data-tracker/#casesper100klast7days
11. Centers for Disease Control and Prevention. Frequently asked questions about COVID-19 vaccinations. Accessed January 23, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html
12. Kaiser Family Foundation. State health facts: population distribution by age 2019. Accessed February 28, 2021. https://www.kff.org/other/state-indicator/distribution-by-age/?currentTimeframe=0&sortModel=%7B%22colId%22:%22%22Locati on%22%2C%22sort%22:%22asc%22%7D

13. Zimlich R. New study urges clinicians to consider needle fears: fear of needles may play a larger role than clinicians think in vaccine compliance, both in the childhood years and beyond. Contemp Pediatr. 2018;35:23.

14. McLenon J, Rogers MAM. The fear of needles: a systematic review and meta-analysis. J Adv Nurs. 2019;75:30.

15. Ayala ES, Meuret AE, Ritz T. Treatments for blood-injury-injection phobia: a critical review of current evidence. J Psychiatric Res. 2009;43:1235-1242. doi:10.1016/j.jpsychires.2009.04.008

16. Stinson FS, Dawson DA, Chou SP, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2007;37:1047-1059.

17. Hamilton JG. Needle phobia: a neglected diagnosis. J Fam Pract. 1995;41:169-175.

18. McMurtry CM, Riddell RP, Taddio A, et al. Far from “just a poke”: common painful needle procedures and the development of needle fear. Clin J Pain. 2015;31:S3-S11. doi:10.1097/AJP.0000000000000272

19. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders: DSM 5. American Psychiatric Association; 2013.

20. Chapman TF, Fyer AJ, Mannuzza S, Klein DF. A comparison of treated and untreated simple phobia. Am J Psychiatry. 1993;150:816-818. doi:10.1176/ajp.150.5.816

21. Van Houtem CMHH, Laine ML, Boomsma DI, Ligthart L, van Wijk AJ, De Jongh A. A review and meta-analysis of the heritability of specific phobia subtypes and corresponding fears. J Anxiety Dis. 2013;27:379-388. doi:10.1016/j.janxdis.2013.04.007

22. Accurso V, Winnicki M, Shamsuzzaman ASM, et al. Predisposition to vasovagal syncope in subjects with blood/injury phobia. Circulation. 2001;104:903-907.

23. Alboni P, Alboni M. Typical vasovagal syncope as a “defense mechanism” for the heart by contrasting sympathetic over-activity. Clin Auton Res. 2017;27:253-261. doi:10.1007/s10286-017-0446-2

24. Bucci LM, MacDonald NE, Freedman T, Taddio A. Benchmarking public health pain management practices during school immunizations. Can Commun Dis Rep. 2020;46:367-372. doi:10.14755/ccdr.v46i10a10

25. Taddio A, Ipp M, Thivakaran S, et al. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine. 2012;30:4807-4812. doi:10.1016/j.vaccine.2012.05.011

26. Marks I. Blood-injury phobia: a review. Am J Psychiatry. 1988;145:1207-1213. doi:10.1176/ajp.145.10.1207

27. Choy Y, Fyer AJ, Lipsitz JD. Treatment of specific phobia in adults. Clin Psychol Rev. 2007;27:266-286. doi:10.1016/j.cpr.2006.10.002

28. Thom A, Sartory G, Johren P. Comparison between one-session psychological treatment and benzodiazepine in dental phobia. J Consult Clin Psychol. 2000;68:378-387. doi:10.1037//0022-006x.68.3.378

29. Wilhelm FH, Roth WT. Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther. 1997;35:831-841. doi:10.1016/s0005-7967(97)00033-8

30. Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev. 2008;28:1021-1037. doi:10.1016/j.cpr.2008.02.007

31. Davis TE, Ollendick TH, Øst L-G. Intensive One-Session Treatment of Specific Phobias. Springer; 2012.

32. Ost LG, Sterner U. Applied tension. A specific behavioral method for treatment of blood phobia. Behav Res Ther. 1987;25:25-29. doi:10.1016/0005-7967(87)90111-2

33. Ost LG, Fellenius J, Sterner U. Applied tension, exposure in vivo, and tension-only in the treatment of blood phobia. Behav Res Ther. 1991;29:561-574. doi:10.1016/0005-7967(91)90006-o

34. Cuijpers P, Marks IM, van Straten A, Cavanagh K, Gega L, Andersson G. Computer-aided psychotherapy for anxiety disorders: a meta-analytic review. Cogn Behav Ther. 2009;38:66-82. doi:10.1080/16506070802694776

35. Wiederhold BK, Wiederhold MD. Three-year follow-up for virtual reality exposure for fear of flying. Cyberpsychol Behav. 2003;6:441-445. doi:10.1089/109493103232278844

36. Meindl JN, Saba S, Gray M, Stuebing L, Jarvis A. Reducing blood draw phobia in an adult with autism spectrum disorder using low-cost virtual reality exposure therapy. J Appl Res Intellect Disabil. 2019;32:1446-1452. doi:10.1111/jar.12637

37. Oppes D, Pintea S, Garcia-Palacios A, Botella C, Szamoskozi S, David D. Virtual reality exposure therapy in anxiety disorders: a quantitative meta-analysis. Depress Anxiety. 2012;29:85-93. doi:10.1002/da.20910

38. Powers MB, Emmelkamp PM. Virtual reality exposure therapy for anxiety disorders: a meta-analysis. J Anxiety Disord. 2008;22:561-569. doi:10.1016/j.janxdis.2007.04.006

39. Garcia-Palacios A, Botella C, Hoffman H, Fabregat S. Comparing acceptance and refusal rates of virtual reality exposure vs. in vivo exposure by patients with specific phobias. Cyberpsychol Behav. 2007;10:722-724. doi:10.1089/cpb.2007.9962